公开(公告)号：US20240360227A1

公开(公告)日：2024-10-31

申请号：US18760539

申请日：2024-07-01

申请人： Viridian Therapeutics, Inc.

发明人： Vahe BEDIAN ,  Yang ZHAO

IPC分类号： C07K16/28 ,  A61K31/7088 ,  A61K35/12 ,  A61P27/02 ,  C07K16/46

CPC分类号： C07K16/2863 ,  A61K31/7088 ,  A61K35/12 ,  A61P27/02 ,  C07K16/461 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/94

摘要： Antibodies and compositions against IGF-1R and uses thereof are provided herein.

公开(公告)号：US20240360226A1

公开(公告)日：2024-10-31

申请号：US18753316

申请日：2024-06-25

申请人： ASTRAZENECA AB

发明人： Frank Irvine COMER ,  Yariv MAZOR ,  Srinath KASTURIRANGAN ,  Qun DU ,  Chunning YANG ,  Andrew Grier BUCHANAN

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61K47/68 ,  A61P1/18 ,  A61P35/00

CPC分类号： C07K16/2863 ,  A61K47/68037 ,  A61K47/6849 ,  A61P1/18 ,  A61P35/00 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/77 ,  C07K2317/92

摘要： The present disclosure relates to antibody molecules that bind epidermal growth factor receptor (EGFR) and/or c-Met and conjugates containing these antibody molecules. The antibody molecules and conjugates find application in the treatment of cancer, for example.

公开(公告)号：US12129303B2

公开(公告)日：2024-10-29

申请号：US18590853

申请日：2024-02-28

申请人： Lassen Therapeutics 1, Inc.

发明人： Robert A. Horlick ,  Helen Toni Jun ,  David J. King

IPC分类号： C07K16/28 ,  A61P11/00

CPC分类号： C07K16/2866 ,  A61P11/00 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

摘要： Provided are antibodies and antigen binding fragments thereof that bind to human interleukin-11 receptor subunit α (IL-11Rα) and related compositions, which may be used in any of a variety of therapeutic or diagnostic methods, including the treatment or diagnosis of cancers, inflammatory diseases, autoimmune diseases, and others.

公开(公告)号：US20240353428A1

公开(公告)日：2024-10-24

申请号：US18599751

申请日：2024-03-08

申请人： ALZPATH, INC.

发明人： Andreas Jeromin ,  Krish Venkat

IPC分类号： G01N33/68 ,  C07K16/18 ,  G01N33/53

CPC分类号： G01N33/6896 ,  C07K16/18 ,  G01N33/53 ,  G01N33/6857 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/565 ,  G01N2333/4704 ,  G01N2333/4709 ,  G01N2333/96416 ,  G01N2800/2821

摘要： Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays.

公开(公告)号：US20240343798A1

公开(公告)日：2024-10-17

申请号：US18682489

申请日：2022-08-09

申请人： GV20 Therapeutics LLC ,  Shanghai XunBaiHui Biotechnology Co., LTD.

发明人： Tengfei Xiao ,  Xihao Hu ,  Xiaole Shirley Liu

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61K45/06 ,  A61P35/04 ,  G01N33/50 ,  G01N33/574 ,  G01N33/68

CPC分类号： C07K16/2803 ,  A61K45/06 ,  A61P35/04 ,  G01N33/5023 ,  G01N33/57492 ,  G01N33/6854 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  G01N2333/70503

摘要： The present invention provides methods and compositions for treating a cancer, and/or an autoimmune disease, by modulating the expression and/or activity of IGSF8 and its binding ligands. The pharmaceutical compositions may include, but are not limited to, antibodies that specifically bind human IGSF8, and have an activity of inhibiting IGSF8-mediated immunosuppression in a subject in need thereof.

公开(公告)号：US20240342405A1

公开(公告)日：2024-10-17

申请号：US18753326

申请日：2024-06-25

申请人： Norton (Waterford) Limited

发明人： Mark Milton-Edwards ,  Guilherme Safioti ,  Lena Granovsky ,  Michael Reich

IPC分类号： A61M15/00 ,  A61B5/00 ,  A61B5/08 ,  A61K31/138 ,  A61M11/00 ,  C07K16/24 ,  C07K16/28 ,  C07K16/42 ,  G16H20/10 ,  G16H20/13 ,  G16H50/30 ,  G16H50/70

CPC分类号： A61M15/009 ,  A61B5/0826 ,  A61B5/4848 ,  A61B5/7275 ,  A61K31/138 ,  A61M15/0001 ,  A61M15/0025 ,  A61M15/003 ,  A61M15/008 ,  A61M15/0091 ,  C07K16/244 ,  C07K16/247 ,  C07K16/2866 ,  C07K16/4291 ,  G16H20/10 ,  G16H20/13 ,  G16H50/30 ,  G16H50/70 ,  A61M11/00 ,  A61M15/0026 ,  A61M2202/064 ,  A61M2205/05 ,  A61M2205/18 ,  A61M2205/3327 ,  A61M2205/3331 ,  A61M2205/3358 ,  A61M2205/3584 ,  A61M2205/502 ,  A61M2205/505 ,  A61M2205/52 ,  A61M2230/30 ,  A61M2230/40 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/52

摘要： Provided is a system for determining a probability of a respiratory disease exacerbation in a subject. The system comprises an inhaler arrangement for delivering a medicament to the subject. The medicament may be a rescue medicament and/or a maintenance medicament. The inhaler arrangement has a use-detection system configured to determine an inhalation performed by the subject using the inhaler arrangement. A sensor system is configured to measure a parameter relating to airflow during the inhalation. A user interface enables user-input of an indication of a status of the respiratory disease being experienced by the subject. A processor is configured to determine the probability of the respiratory disease exacerbation based on the recorded inhalation(s) from the use-detection system, the parameter(s) received from the sensor system, and the indication received from the user interface. Further provided is a method for determining the probability of a respiratory disease exacerbation in a subject.

公开(公告)号：US20240336682A1

公开(公告)日：2024-10-10

申请号：US18293500

申请日：2022-07-27

申请人： SHENGHE (CHINA) BIOPHARMACEUTICAL CO., LTD.

发明人： Chong ZHOU ,  Liusong YIN ,  Xiaoling JIANG

IPC分类号： C07K16/28

CPC分类号： C07K16/2803 ,  C07K16/2863 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/569 ,  C07K2317/734 ,  C07K2317/76

摘要： A multispecific antigen-binding protein including: (a) a first antigen-binding portion capable of recognizing the first antigen, where the first antigen is a tumor-associated antigen (TAA); (b) a second antigen-binding portion, where the second antigen-binding portion is an innate immune cell agonist; and (c) a third antigen-binding portion capable of recognizing the third antigen, where the third antigen regulates the tumor microenvironment. The embodiments further provide a pharmaceutical composition including the multispecific antigen-binding protein and a pharmaceutically acceptable carrier, and use of the multispecific antigen-binding protein and the pharmaceutical composition in the preparation of a drug for the treatment of cancer.

公开(公告)号：US12103964B2

公开(公告)日：2024-10-01

申请号：US17056384

申请日：2019-05-17

申请人： CZ Biohub SF LLC ,  The Board of Trustees of the Leland Stanford Junior University

发明人： Derek Croote ,  Stephen R. Quake ,  Kari Nadeau ,  Spyros Darmanis ,  David N. Cornfield

IPC分类号： C07K16/00 ,  A61K39/395 ,  A61K49/00 ,  C07K16/14 ,  C07K16/16 ,  C07K16/18 ,  C12N5/0781 ,  G01N33/50 ,  G01N33/569

CPC分类号： C07K16/18 ,  A61K39/39575 ,  A61K49/0004 ,  C07K16/14 ,  C07K16/16 ,  C12N5/0635 ,  G01N33/5052 ,  G01N33/56961 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/92

摘要： In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen.

公开(公告)号：US20240317841A1

公开(公告)日：2024-09-26

申请号：US18253383

申请日：2021-11-19

申请人： Vir Biotechnology, Inc. ,  Humabs BioMed SA

发明人： Davide CORTI ,  Matteo Samuele PIZZUTO ,  Fabrizia ZATTA ,  Elisabetta CAMERONI ,  Gyorgy SNELL

IPC分类号： C07K16/10 ,  A61K39/00 ,  A61P31/16

CPC分类号： C07K16/1018 ,  A61P31/16 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/72 ,  C07K2317/76 ,  C07K2317/92

摘要： The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to an influenza A virus hemagglutinin (HA) and can neutralize a IAV infection. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors that comprise such polynucleotides, host cells that can express the antibodies or antigen-binding fragments, related compositions, and methods of using the herein disclosed compositions to, for example, treat or prevent an IAV infection.

公开(公告)号：US20240301062A1

公开(公告)日：2024-09-12

申请号：US18620439

申请日：2024-03-28

申请人： BeiGene Switzerland GmbH

发明人： Liu XUE ,  Ming LEI ,  Yao DING ,  Ruyue JI ,  Yun CHEN

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61K47/22 ,  A61K47/26 ,  A61P35/00

CPC分类号： C07K16/2809 ,  A61K47/22 ,  A61K47/26 ,  A61P35/00 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/734

摘要： The present disclosure provides for antibodies and antigen-binding fragments thereof that bind to human CD3, a pharmaceutical composition comprising said antibody or antigen-binding fragments thereof, and use of the antibody or antigen-binding fragments thereof or the composition for treating a disease, such as cancer.